Glen B. Baker, PhD, DSc

Professor and Vice Chair (Research), Department of Psychiatry; Professor of Neuroscience, Faculty of Medicine & Dentistry, University of Alberta

Research Interests

Mechanisms of action of antidepressant and anxiolytic drugs.

Biochemical bases of psychiatric disorders, with emphasis on depression and anxiety disorders.

Development of analytical techniques for measuring amino acids, biogenic amines, neuroactive steroids psychiatric drugs and their metabolites in tissues and body fluids

Drug metabolism and drug-drug interactions:  I am interested in the role of metabolism in the actions of psychiatric drugs since many of them are extensively metabolised and/or undergo metabolic interactions with other drugs that are coadministered.  In addition, metabolites often contribute significantly to the therapeutic effects and/or side effect profiles of the drugs. 

Roles of amino acids (primarily GABA, glutamate, serine glycine and alanine) in the etiology and pharmacotherapy of neuropsychiatric disorders.

The development and testing of potential new neuroprotective agents


Rotzinger S, Fang J, Coutts RT, and Baker GB (1998).
Human CYP2D6 and metabolism of m-chlorophenylpiperazine (mCPP). Biological Psychiatry 44:1185-1191.


Baker GB, Urichuk LJ, McKenna KF, and Kennedy SH (1999). Metabolism of monoamine oxidase inhibitors. Cellular and Molecular Neurobiology 19:411-426.


Parent M, Habib MK, and Baker GB (2000). Time-dependent changes in brain monoamine oxidase activity and in brain levels of monoamines and amino acids following acute administration of the antidepressant/antipanic drug phenelzine. Biochemical Pharmacology 59:1253-1263.


Tanay VA-MI, Greenshaw AJ, Baker GB, Bateson AN (2001). Common effects of chronically administered antipanic drugs on brainstem GABAA receptor subunit gene expression. Molecular Psychiatry 6:404-412.


Baker GB and Prior TI. (2002). Stereochemistry and drug efficacy and development: Relevance of chirality to antidepressant and antipsychotic drugs. Annals of Medicine, 34:537-543.


Kapur, S., McClelland, R.A., VanderSpek, S.C., Wadenberg, M.L., Baker, G.B., Nobrega, J., Zipursky, R.B. and Seeman, P. (2002) Increasing D2 affinity results in the loss of clozapine’s atypical antipsychotic action. NeuroReport 13: 831-835.


Prior, T.I. and Baker, G.B. (2003). Interactions between the cytochrome P450 system and the second-generation antipsychotics. J. Psychiatry. Neurosci. 28: 99-112.


Lara, N., Archer, S., Baker, G.B. and LeMelledo, J.M. (2003) Paroxetine-induced increase in metabolic end products of nitric oxide. J. Clin. Psychopharmacol. 23:1-5.


Sowa, B., Todd, K.G., Tanay, V.A.M.I., Holt, A. and Baker, G.B. (2004) Monoamine oxidase inhibitors and development of neuroprotective drugs. Current Neuropharmacol. 2:153-168..


Duffy, S., Nguyen, P.V. and Baker, G.B. (2004). Phenylethylidenehydrazine, a novel GABA-transaminase inhibitor, suppresses epileptiform activity in rat hippocampal slices. Neuroscience 126: 423-432.


Kennedy, S.H., Holt, A., and Baker, G.B. (2005) Monoamine oxidase inhibitors.  In Kaplan and Sadock’s Comprehensive textbook of psychiatry Eighth Edititon (Sadock, B. and Sadock, V.A., eds.) Lippincott Williams and Williams, Philadelphia, pp. 2854-2863.


Wood, P., Khan M.A., Moskal, J.R., Todd, K.G., Tanay, V.  A.M.I., and Baker, G.B. (2006) Aldehyde load in ischemia-reperfusion brain injury: Neuroprotection by neutralization of reactive aldehydes with phenelzine. Brain Res. (in press).


MacKenzie, E.M., Odontiadis, J., Le Melledo, J-M., Prior, T.I. and Baker, G.B. (2006).  The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.  Cell. Mol. Neurobiol.  (in press).


Contact me